The biopharmaceutical industry maintained roughly the same reputation in 2013 as in 2012, with an overall reputation index of 60.5, but the industry's reputation among policymakers slid from 58.6 to 55.3, a stakeholder survey by APCO Worldwide found. Vulnerabilities include affordability, pricing transparency, executive management and governance, and stakeholders expressed concern about responsible marketing. Strengths include product safety, manufacturing and product transparency.

Related Summaries